@article{article, title = {{Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial}}, publisher = {{BMJ}}, url = {{http://dx.doi.org/10.1136/bmjopen-2023-083582 }}, year = {{2024}}, month = {{2}}, author = {{Brittain G and Petrie J and Duffy KEM and Glover R and Hullock K and Papaioannou D and Roldan E and Beecher C and Bursnall M and Ciccarelli O and Coles AJ et al}}, doi = {{10.1136/bmjopen-2023-083582}}, volume = {{14}}, journal = {{BMJ Open}}, issue = {{2}}, pages = {{e083582-e083582}}, note = {{Accessed on 2025/05/21}}}